$OGN

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Organon (NYSE:OGN) reported a miss on Wall Street's revenue and earnings expectations for Q1 CY2026, with sales declining 3.5% year-on-year to $1.46 billion and adjusted EPS coming in 16.8% below consensus at $0.71. The company has shown a struggle with consistent revenue growth and decreasing profitability over the past several years. Analysts anticipate revenue to remain flat and full-year EPS to grow marginally in the next 12 months, highlighting ongoing challenges for the pharmaceutical firm.

Original reporting
StockStory · Jabin Bastian
Published May 1, 2026, 2:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates — source image
Decision brief

The 30-second read

$OGNBearishMed
01

Why it matters

The earnings miss has led to increased bearish sentiment, affecting stock price and investor confidence.

02

Market read

The news is highly relevant for traders and investors holding or considering OGN, especially in the short term.

03

What to watch

Potential upcoming catalysts such as pipeline approvals or strategic partnerships that could offset recent setbacks.

Timing: short-term (next 1-3 months)

Background

Organon has faced ongoing challenges with revenue growth and profitability, reflected in recent earnings reports.

Company-level read

Ticker impact

$OGNBearishMedium confidence
Context

Primary focus due to recent earnings miss and bearish sentiment.

Expected impact

Moderate downward pressure expected in the short term, with potential for further decline if negative trends persist.

Evidence & confidence

The recent earnings miss and bearish sentiment indicate a risk of continued weakness. However, the company's long-term prospects depend on future recovery efforts and industry conditions.

Market effects

Potential negative impact on the pharmaceutical and life sciences sectors due to earnings disappointment.

Limited regional impact; primarily affects US-based pharmaceutical stocks.

Moderate; sector-wide implications may influence global healthcare markets.

Counterpoint

Some analysts believe the earnings miss is a short-term anomaly, and the company's fundamentals remain solid, potentially leading to a rebound.

Key entities

  • Organon & Co.

    A global healthcare company focusing on reproductive health, oncology, and other therapeutic areas.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.